3 completed, 3 not yet recruiting. 2 Not applicable, 2 Phase 2, 2 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 2 | Not yet recruiting 2 |
| Phase 2 | 2 | Completed 1, Not yet recruiting 1 |
| Phase 4 | 2 | Completed 2 |
Follow Bing Han: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Efficacy and Safety of Selinisole Combined With Azacitidine and Venetoclax in the Treatment of Newly Diagnosed High-risk Myeloid Tumors With TP53 Mutations Selinexor - Myeloid Tumors | Not applicable | Not yet recruiting | Bing Han | 30 | 2026-11-01 | 2026-06-08 |
| A Single-arm Phase 2 Prospective Clinical Study of Enatumab in the Treatment of Relapsed/Refractory Warm Antibody Autoimmune Hemolytic Anemia enatumab - Autoimmune Hemolytic Anemia | Phase 2 | Not yet recruiting | Bing Han | 3 | 2025-09-18 | 2025-09-24 |
| A Multicenter Prospective Study of Iptacopan in the Treatment of Refractory/Relapsed Autoimmune Hemolytic Anemia (AIHA) Iptacopan - AIHA - Warm Autoimmune Hemolytic Anemia, AIHA - Cold Autoimmune Hemolytic Anemia | Not applicable | Not yet recruiting | Bing Han | 20 | 2025-03-01 | 2025-02-26 |
| Efficacy and Safety in Transfusion Independent Non-severe Aplastic Anemia Luspatercept, Cyclosporine - Aplastic Anemia | Phase 2 | Completed | Bing Han | 58 | 2022-12-19 | 2025-09-16 |
| Sirolimus Treatment for Newly Diagnosed Primary Acquired PRCA Sirolimus, Cyclosporine A - Pure Red Cell Aplasia, Acquired | Phase 4 | Completed | Bing Han | 56 | 2020-07-01 | 2023-02-28 |
| Sirolimus Treatment for Refractory PRCA Sirolimus - Pure Red Cell Aplasia | Phase 4 | Completed | Bing Han | 64 | 2018-02-01 | 2021-07-06 |
Anemia, Hemolytic, Autoimmune (2) · Red-Cell Aplasia, Pure (2) · Anemia, Aplastic (1)
Cyclosporine (2) · Sirolimus (2) · Azacitidine (1) · iptacopan (1) · luspatercept (1) · selinexor (1) · venetoclax (1)
China (6)
Bing B Han, PhD. (1)
PMID 19208097, PMID 24363761, PMID 26504182, PMID 27881371, PMID 29982851, PMID 32030447, PMID 37160872, PMID 42057135